Cargando…

The Performance of Immunoassays to Measure Antibodies to the Chlamydia trachomatis Antigen Pgp3 in Different Epidemiological Settings for Trachoma

Programs to eliminate trachoma as a public health problem use prevalence of the clinical sign trachomatous inflammation—follicular (TF) in 1- to 9-year-olds in endemic districts to make decisions to begin or end mass drug administration with azithromycin. Trachomatous inflammation—follicular is used...

Descripción completa

Detalles Bibliográficos
Autores principales: Gwyn, Sarah, Nute, Andrew W., Sata, Eshetu, Tadesse, Zerihun, Chernet, Ambahun, Haile, Mahteme, Zeru, Taye, Bethea, Danaya, Laurent, Christian, Callahan, E. Kelly, Nash, Scott D., Martin, Diana L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Tropical Medicine and Hygiene 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8592184/
https://www.ncbi.nlm.nih.gov/pubmed/34398819
http://dx.doi.org/10.4269/ajtmh.21-0541
_version_ 1784599408894017536
author Gwyn, Sarah
Nute, Andrew W.
Sata, Eshetu
Tadesse, Zerihun
Chernet, Ambahun
Haile, Mahteme
Zeru, Taye
Bethea, Danaya
Laurent, Christian
Callahan, E. Kelly
Nash, Scott D.
Martin, Diana L.
author_facet Gwyn, Sarah
Nute, Andrew W.
Sata, Eshetu
Tadesse, Zerihun
Chernet, Ambahun
Haile, Mahteme
Zeru, Taye
Bethea, Danaya
Laurent, Christian
Callahan, E. Kelly
Nash, Scott D.
Martin, Diana L.
author_sort Gwyn, Sarah
collection PubMed
description Programs to eliminate trachoma as a public health problem use prevalence of the clinical sign trachomatous inflammation—follicular (TF) in 1- to 9-year-olds in endemic districts to make decisions to begin or end mass drug administration with azithromycin. Trachomatous inflammation—follicular is used as a proxy for transmission of ocular Chlamydia trachomatis infection. Long-term monitoring of previously endemic districts for recrudescence of ocular C. trachomatis infection would benefit from a simple blood test that could be integrated with other public health programs. In this study, we evaluated multiple tests to measure antibodies against the C. trachomatis antigen Pgp3—a multiplex bead assay (MBA), an ELISA, and two versions of a lateral flow assay (LFA)—in four districts of the Amhara region of Ethiopia with varying levels of TF. Seroprevalence and seroconversion rate (SCR) results were proportional to TF prevalence by district for most tests, with the notable exception of the LFA using colloidal gold as the developing reagent. Changing the test developing reagent to black latex improved agreement between serological measures and TF prevalence and in inter-rater agreement. Seroconversion rate estimates using data derived from the LFA-gold assay were inconsistent with the shape of the age-seroprevalence curve, which did not increase in older ages. These data revealed potential complications with using SCR that will need further evaluation. Data from MBA, ELISA, and LFA with the black test line showed good agreement with each other and proportionality to TF estimates, providing further data that serology has potential utility for trachoma surveillance.
format Online
Article
Text
id pubmed-8592184
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The American Society of Tropical Medicine and Hygiene
record_format MEDLINE/PubMed
spelling pubmed-85921842021-11-24 The Performance of Immunoassays to Measure Antibodies to the Chlamydia trachomatis Antigen Pgp3 in Different Epidemiological Settings for Trachoma Gwyn, Sarah Nute, Andrew W. Sata, Eshetu Tadesse, Zerihun Chernet, Ambahun Haile, Mahteme Zeru, Taye Bethea, Danaya Laurent, Christian Callahan, E. Kelly Nash, Scott D. Martin, Diana L. Am J Trop Med Hyg Article Programs to eliminate trachoma as a public health problem use prevalence of the clinical sign trachomatous inflammation—follicular (TF) in 1- to 9-year-olds in endemic districts to make decisions to begin or end mass drug administration with azithromycin. Trachomatous inflammation—follicular is used as a proxy for transmission of ocular Chlamydia trachomatis infection. Long-term monitoring of previously endemic districts for recrudescence of ocular C. trachomatis infection would benefit from a simple blood test that could be integrated with other public health programs. In this study, we evaluated multiple tests to measure antibodies against the C. trachomatis antigen Pgp3—a multiplex bead assay (MBA), an ELISA, and two versions of a lateral flow assay (LFA)—in four districts of the Amhara region of Ethiopia with varying levels of TF. Seroprevalence and seroconversion rate (SCR) results were proportional to TF prevalence by district for most tests, with the notable exception of the LFA using colloidal gold as the developing reagent. Changing the test developing reagent to black latex improved agreement between serological measures and TF prevalence and in inter-rater agreement. Seroconversion rate estimates using data derived from the LFA-gold assay were inconsistent with the shape of the age-seroprevalence curve, which did not increase in older ages. These data revealed potential complications with using SCR that will need further evaluation. Data from MBA, ELISA, and LFA with the black test line showed good agreement with each other and proportionality to TF estimates, providing further data that serology has potential utility for trachoma surveillance. The American Society of Tropical Medicine and Hygiene 2021-11 2021-08-16 /pmc/articles/PMC8592184/ /pubmed/34398819 http://dx.doi.org/10.4269/ajtmh.21-0541 Text en © The American Society of Tropical Medicine and Hygiene https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Article
Gwyn, Sarah
Nute, Andrew W.
Sata, Eshetu
Tadesse, Zerihun
Chernet, Ambahun
Haile, Mahteme
Zeru, Taye
Bethea, Danaya
Laurent, Christian
Callahan, E. Kelly
Nash, Scott D.
Martin, Diana L.
The Performance of Immunoassays to Measure Antibodies to the Chlamydia trachomatis Antigen Pgp3 in Different Epidemiological Settings for Trachoma
title The Performance of Immunoassays to Measure Antibodies to the Chlamydia trachomatis Antigen Pgp3 in Different Epidemiological Settings for Trachoma
title_full The Performance of Immunoassays to Measure Antibodies to the Chlamydia trachomatis Antigen Pgp3 in Different Epidemiological Settings for Trachoma
title_fullStr The Performance of Immunoassays to Measure Antibodies to the Chlamydia trachomatis Antigen Pgp3 in Different Epidemiological Settings for Trachoma
title_full_unstemmed The Performance of Immunoassays to Measure Antibodies to the Chlamydia trachomatis Antigen Pgp3 in Different Epidemiological Settings for Trachoma
title_short The Performance of Immunoassays to Measure Antibodies to the Chlamydia trachomatis Antigen Pgp3 in Different Epidemiological Settings for Trachoma
title_sort performance of immunoassays to measure antibodies to the chlamydia trachomatis antigen pgp3 in different epidemiological settings for trachoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8592184/
https://www.ncbi.nlm.nih.gov/pubmed/34398819
http://dx.doi.org/10.4269/ajtmh.21-0541
work_keys_str_mv AT gwynsarah theperformanceofimmunoassaystomeasureantibodiestothechlamydiatrachomatisantigenpgp3indifferentepidemiologicalsettingsfortrachoma
AT nuteandreww theperformanceofimmunoassaystomeasureantibodiestothechlamydiatrachomatisantigenpgp3indifferentepidemiologicalsettingsfortrachoma
AT sataeshetu theperformanceofimmunoassaystomeasureantibodiestothechlamydiatrachomatisantigenpgp3indifferentepidemiologicalsettingsfortrachoma
AT tadessezerihun theperformanceofimmunoassaystomeasureantibodiestothechlamydiatrachomatisantigenpgp3indifferentepidemiologicalsettingsfortrachoma
AT chernetambahun theperformanceofimmunoassaystomeasureantibodiestothechlamydiatrachomatisantigenpgp3indifferentepidemiologicalsettingsfortrachoma
AT hailemahteme theperformanceofimmunoassaystomeasureantibodiestothechlamydiatrachomatisantigenpgp3indifferentepidemiologicalsettingsfortrachoma
AT zerutaye theperformanceofimmunoassaystomeasureantibodiestothechlamydiatrachomatisantigenpgp3indifferentepidemiologicalsettingsfortrachoma
AT betheadanaya theperformanceofimmunoassaystomeasureantibodiestothechlamydiatrachomatisantigenpgp3indifferentepidemiologicalsettingsfortrachoma
AT laurentchristian theperformanceofimmunoassaystomeasureantibodiestothechlamydiatrachomatisantigenpgp3indifferentepidemiologicalsettingsfortrachoma
AT callahanekelly theperformanceofimmunoassaystomeasureantibodiestothechlamydiatrachomatisantigenpgp3indifferentepidemiologicalsettingsfortrachoma
AT nashscottd theperformanceofimmunoassaystomeasureantibodiestothechlamydiatrachomatisantigenpgp3indifferentepidemiologicalsettingsfortrachoma
AT martindianal theperformanceofimmunoassaystomeasureantibodiestothechlamydiatrachomatisantigenpgp3indifferentepidemiologicalsettingsfortrachoma
AT gwynsarah performanceofimmunoassaystomeasureantibodiestothechlamydiatrachomatisantigenpgp3indifferentepidemiologicalsettingsfortrachoma
AT nuteandreww performanceofimmunoassaystomeasureantibodiestothechlamydiatrachomatisantigenpgp3indifferentepidemiologicalsettingsfortrachoma
AT sataeshetu performanceofimmunoassaystomeasureantibodiestothechlamydiatrachomatisantigenpgp3indifferentepidemiologicalsettingsfortrachoma
AT tadessezerihun performanceofimmunoassaystomeasureantibodiestothechlamydiatrachomatisantigenpgp3indifferentepidemiologicalsettingsfortrachoma
AT chernetambahun performanceofimmunoassaystomeasureantibodiestothechlamydiatrachomatisantigenpgp3indifferentepidemiologicalsettingsfortrachoma
AT hailemahteme performanceofimmunoassaystomeasureantibodiestothechlamydiatrachomatisantigenpgp3indifferentepidemiologicalsettingsfortrachoma
AT zerutaye performanceofimmunoassaystomeasureantibodiestothechlamydiatrachomatisantigenpgp3indifferentepidemiologicalsettingsfortrachoma
AT betheadanaya performanceofimmunoassaystomeasureantibodiestothechlamydiatrachomatisantigenpgp3indifferentepidemiologicalsettingsfortrachoma
AT laurentchristian performanceofimmunoassaystomeasureantibodiestothechlamydiatrachomatisantigenpgp3indifferentepidemiologicalsettingsfortrachoma
AT callahanekelly performanceofimmunoassaystomeasureantibodiestothechlamydiatrachomatisantigenpgp3indifferentepidemiologicalsettingsfortrachoma
AT nashscottd performanceofimmunoassaystomeasureantibodiestothechlamydiatrachomatisantigenpgp3indifferentepidemiologicalsettingsfortrachoma
AT martindianal performanceofimmunoassaystomeasureantibodiestothechlamydiatrachomatisantigenpgp3indifferentepidemiologicalsettingsfortrachoma